# Lab1636 and Harvard University RFA on Rare Genetic Diseases October 27, 2020 Harvard’s Office of Technology Development ([https://otd.harvard.edu](http://otd.harvard.edu)) is pleased to announce a Request for Applications (RFA) under the strategic research alliance between **Harvard University** and **Lab1636**. This 2020 RFA with Lab1636 and Harvard University is seeking proposals to develop innovative therapeutic strategies for **Rare Genetic Diseases.** Letter of Intents (LOIs) are due **December 4, 2020 at 5:00 pm**. PIs must be faculty of FAS, SEAS, HMS, etc. Postdocs and research scientists can apply jointly with a PI. Harvard University and Deerfield Management, a healthcare investment firm, established a major strategic R&D alliance in 2019 to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield committed up to **$100 million** in initial funding to support the alliance. The [attached document ](/file_url/2805)provides more details on the topic of interest, LOI submission, review and selection process, eligibility and collaborations, and award terms and conditions. Please reach out to your [Business Development](http://otd.harvard.edu/about/team/business-development/) contact within OTD or contact us at if you need any additional information. We look forward to hearing from you! --- Attachments- [ picture\_as\_pdf 2020\_lab1636\_harvard\_rare\_genetic\_diseases\_rfa\_-\_guidelines.pdf ](/sites/g/files/omnuum10026/files/hsci/files/2020_lab1636_harvard_rare_genetic_diseases_rfa_-_guidelines.pdf) --- See also:- [ Announcement ](/news-type/announcement) - [ 2020 ](/year/2020) Share on:- [ Facebook ](#) - [ Twitter ](#) - [ Linkedin ](#)